查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2034244

急性肺損傷治療市場：市場洞察、競爭格局與市場預測（2033 年）

Acute Lung Injury Treatment Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 192 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

隨著全球醫療體係不斷加強對嚴重呼吸道疾病的應對，急性肺損傷治療市場正穩定成長。急性肺損傷（ALI），包括急性呼吸窘迫症候群（ARDS），由於其複雜的病理機制和高死亡率，仍是一項重大挑戰。呼吸道感染疾病、敗血症、創傷和環境風險因素的日益增多，進一步凸顯了有效治療性介入的必要性。醫療專業人員越來越重視早期診斷和先進的治療策略，以提高存活率和患者預後。重症醫學的不斷進步，以及人們對呼吸系統健康的日益關注，共同推動了已開發國家和開發中國家這一市場的擴張。

市場洞察

預計急性肺損傷治療市場規模將從2026年的31億美元成長到2033年的39億美元，預測期內年複合成長率（CAGR）為3.30%。該成長主要受重症監護和呼吸輔助性治療需求不斷成長的推動。藥物治療以及機械呼吸系統護理和氧氣療法仍然是治療方案的關鍵組成部分。此外，體外膜氧合（ECMO）在重症病例中的應用日益廣泛，也提高了嚴重患者的存活率。目的是減輕發炎和改善肺功能的生物製藥和標靶治療的創新也對市場產生了積極影響。隨著臨床研究的不斷發展，治療方法正變得更加個人化和有效。

市場促進因素

呼吸系統疾病的日益流行是急性肺損傷治療市場的主要促進因素。肺炎、膿毒性肺損傷和創傷相關併發症等疾病在全球範圍內不斷增加，推動了對先進治療方案的需求。空氣污染和吸煙等環境因素進一步加劇了肺部健康問題。老年人尤其容易患呼吸系統疾病，這顯著促進了市場成長。此外，加護病房收治的患者數量不斷增加，導致人工呼吸器和氧氣供應系統的使用量增加。持續進行的目的是改善治療效果和最大限度減少副作用的研發活動也在加速市場擴大。

商業機會

該市場為製藥和生物技術公司提供了巨大的成長機會。包括抗發炎藥物、生物製藥和再生醫學在內的創新藥物的研發有望徹底改變治療方式。投資幹細胞治療方法和精準醫療方法的公司有望獲得競爭優勢。此外，對先進呼吸支援設備日益成長的需求也為醫療設備製造商帶來了機會。新興經濟體，特別是亞太和拉丁美洲地區，由於醫療基礎設施的改善和醫療投資的增加，開闢新的成長途徑。戰略夥伴關係和合作有望推動創新並擴大市場覆蓋範圍。

區域分析

北美在急性肺損傷治療市場佔據主導地位，這得益於其先進的醫療基礎設施、高額的醫療費用支出以及主要行業參與者的強大影響力。該地區也受益於廣泛的研發活動和有利的償付政策。歐洲緊跟在北美之後，呈現強勁成長動力，這主要得益於人們對呼吸系統疾病日益成長的認知以及各國政府加強重症監護服務的舉措。亞太地區預計將在預測期內實現最快成長，這主要歸功於其龐大的患者群體、呼吸系統疾病發病率的上升以及醫療設施的普及。拉丁美洲以及中東和非洲地區正逐步崛起為重要的市場，這得益於對醫療體系的持續投資以及先進治療技術的日益普及。

主要企業

  • GlaxoSmithKline plc
  • Bayer AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Octapharma AG
  • Ono Pharmaceutical Co., Ltd.
  • Asklepion Pharmaceuticals, LLC
  • Edesa Biotech
  • Direct Biologics
  • Windtree Therapeutics, Inc.
  • Apeiron Biologics AG
  • ReAlta Life Sciences, Inc.
  • Stemedica Cell Technologies, Inc.
  • Histocell

區隔

依治療方法

  • 藥物治療
  • 氧氣療法
  • 人工呼吸
  • 體外膜氧合（ECMO）

依藥物類別

  • 皮質類固醇
  • 抗生素
  • 支氣管擴張劑
  • 利尿劑
  • 血管擴張劑
  • 其他

依適應症

  • 急性呼吸窘迫症候群（ARDS）
  • 肺炎造成的肺損傷
  • 膿毒症引起的肺損傷
  • 創傷相關的肺損傷
  • 其他

依給藥途徑

  • 靜脈
  • 口服
  • 吸入

依通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房

依地區

  • 北美洲
  • 北美洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

目錄

第1章 執行摘要

第2章 市場概覽

  • 市場定義與細分
  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機會
  • 價值鏈分析
  • 新冠疫情影響分析
  • 波特五力分析
  • 俄烏衝突的影響
  • PESTLE分析
  • 監管分析
  • 價格趨勢分析
    • 當前價格及未來預測（2025-2033）
    • 價格影響因素

第3章 2020-2033年全球急性肺損傷治療市場展望

  • 全球急性肺損傷治療市場展望，依治療方法分類，價值（十億美元），2020-2033年
    • 藥物治療
    • 氧氣療法
    • 人工呼吸器
    • 體外膜氧合（ECMO）
  • 全球急性肺損傷治療市場展望，依藥物類別分類，價值（十億美元），2020-2033年
    • 皮質類固醇
    • 抗生素
    • 支氣管擴張劑
    • 利尿劑
    • 血管擴張劑
    • 其他
  • 全球急性肺損傷治療市場展望，依適應症，價值（十億美元），2020-2033年
    • 急性呼吸窘迫症候群（ARDS）
    • 肺炎造成的肺損傷
    • 膿毒性肺損傷
    • 創傷性肺損傷
    • 其他
  • 全球急性肺損傷治療市場展望，依給藥途徑分類，價值（十億美元），2020-2033年
    • 靜脈
    • 口服
    • 吸入
  • 全球急性肺損傷治療市場展望，依通路分類，價值（十億美元），2020-2033年
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 全球急性肺損傷治療市場展望，依地區分類，價值（十億美元），2020-2033年
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第4章 2020-2033年北美急性肺損傷治療市場展望

第5章 2020-2033年歐洲急性肺損傷治療市場展望

第6章 2020-2033年亞太地區急性肺損傷治療市場展望

第7章 2020-2033年拉丁美洲急性肺損傷治療市場展望

第8章 2020-2033年中東及非洲急性肺損傷治療市場展望

第9章 競爭情勢

  • 公司與細分市場熱圖
  • 2025年各公司市場佔有率分析
  • 競爭儀錶板
  • 公司簡介
    • GlaxoSmithKline plc
    • Bayer AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Octapharma AG
    • Ono Pharmaceutical Co., Ltd.
    • Asklepion Pharmaceuticals, LLC
    • Edesa Biotech
    • Direct Biologics
    • Windtree Therapeutics, Inc.
    • Apeiron Biologics AG
    • ReAlta Life Sciences, Inc.
    • Stemedica Cell Technologies, Inc.
    • Histocell

第10章 附錄

簡介目錄

The Acute Lung Injury Treatment Market is steadily evolving as global healthcare systems intensify efforts to address severe respiratory conditions. Acute lung injury (ALI), including acute respiratory distress syndrome (ARDS), continues to present a critical burden due to its complex pathology and high fatality rates. The increasing incidence of respiratory infections, sepsis, trauma, and environmental risk factors has amplified the need for effective therapeutic interventions. Healthcare providers are increasingly focusing on early diagnosis and advanced treatment strategies to improve survival rates and patient outcomes. Continuous advancements in critical care medicine, combined with rising awareness about respiratory health, are contributing to the expansion of this market across developed and developing regions.

Market Insights

The Acute Lung Injury Treatment Market is projected to expand from 3.1 billion in 2026 to 3.9 billion by 2033, reflecting a compound annual growth rate (CAGR) of 3.30% over the forecast period. This growth is supported by increasing demand for intensive care treatments and supportive respiratory therapies. Pharmacological interventions, along with mechanical ventilation and oxygen therapy, remain key components of treatment protocols. Additionally, the adoption of extracorporeal membrane oxygenation (ECMO) is gaining traction in severe cases, enhancing survival rates in critical conditions. The market is also benefiting from innovations in biologics and targeted therapies that aim to reduce inflammation and improve lung function. As clinical research continues to evolve, treatment approaches are becoming more personalized and effective.

Market Drivers

The rising prevalence of respiratory diseases is a major factor driving the Acute Lung Injury Treatment Market. Conditions such as pneumonia, sepsis-induced lung injury, and trauma-related complications are increasing globally, leading to higher demand for advanced treatment solutions. Environmental factors such as air pollution and smoking further exacerbate lung health issues. The aging population is particularly vulnerable to respiratory disorders, contributing significantly to market growth. Additionally, the growing number of hospital admissions in intensive care units has increased the use of ventilators and oxygen support systems. Ongoing research and development activities focused on improving therapeutic outcomes and minimizing adverse effects are also accelerating market expansion.

Business Opportunity

The market offers considerable growth opportunities for pharmaceutical and biotechnology companies. The development of innovative drugs, including anti-inflammatory agents, biologics, and regenerative therapies, is expected to reshape the treatment landscape. Companies investing in stem cell-based therapies and precision medicine approaches are likely to gain a competitive advantage. Furthermore, the increasing demand for advanced respiratory support devices presents opportunities for medical device manufacturers. Emerging economies, particularly in Asia Pacific and Latin America, are creating new avenues for growth due to improving healthcare infrastructure and rising healthcare investments. Strategic partnerships and collaborations are anticipated to drive innovation and expand market reach.

Region Analysis

North America holds a dominant position in the Acute Lung Injury Treatment Market, supported by advanced healthcare infrastructure, high healthcare expenditure, and a strong presence of leading industry players. The region also benefits from extensive research and development activities and favorable reimbursement policies. Europe follows closely, driven by increasing awareness of respiratory diseases and government initiatives to enhance critical care services. The Asia Pacific region is expected to witness the fastest growth during the forecast period due to a large patient population, rising incidence of respiratory conditions, and expanding access to healthcare facilities. Latin America and the Middle East & Africa are gradually emerging as important markets, supported by ongoing investments in healthcare systems and increasing adoption of advanced treatment technologies.

Key Players

  • GlaxoSmithKline plc
  • Bayer AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Octapharma AG
  • Ono Pharmaceutical Co., Ltd.
  • Asklepion Pharmaceuticals, LLC
  • Edesa Biotech
  • Direct Biologics
  • Windtree Therapeutics, Inc.
  • Apeiron Biologics AG
  • ReAlta Life Sciences, Inc.
  • Stemedica Cell Technologies, Inc.
  • Histocell

Segmentation

By Treatment Type

  • Pharmacological Therapy
  • Oxygen Therapy
  • Mechanical Ventilation
  • Extracorporeal Membrane Oxygenation (ECMO)

By Drug Class

  • Corticosteroids
  • Antibiotics
  • Bronchodilators
  • Diuretics
  • Vasodilators
  • Others

By Indication

  • Acute Respiratory Distress Syndrome (ARDS)
  • Pneumonia-induced Lung Injury
  • Sepsis-induced Lung Injury
  • Trauma-related Lung Injury
  • Others

By Route of Administration

  • Intravenous
  • Oral
  • Inhalation

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Acute Lung Injury Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 3.1. Global Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Pharmacological Therapy
    • 3.1.2. Oxygen Therapy
    • 3.1.3. Mechanical Ventilation
    • 3.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 3.2. Global Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.2.1. Corticosteroids
    • 3.2.2. Antibiotics
    • 3.2.3. Bronchodilators
    • 3.2.4. Diuretics
    • 3.2.5. Vasodilators
    • 3.2.6. Others
  • 3.3. Global Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 3.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 3.3.2. Pneumonia-induced Lung Injury
    • 3.3.3. Sepsis-induced Lung Injury
    • 3.3.4. Trauma-related Lung Injury
    • 3.3.5. Others
  • 3.4. Global Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.4.1. Intravenous
    • 3.4.2. Oral
    • 3.4.3. Inhalation
  • 3.5. Global Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.5.1. Hospital Pharmacies
    • 3.5.2. Retail Pharmacies
    • 3.5.3. Online Pharmacies
  • 3.6. Global Acute Lung Injury Treatment Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.6.1. North America
    • 3.6.2. Europe
    • 3.6.3. Asia Pacific
    • 3.6.4. Latin America
    • 3.6.5. Middle East & Africa

4. North America Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 4.1. North America Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Pharmacological Therapy
    • 4.1.2. Oxygen Therapy
    • 4.1.3. Mechanical Ventilation
    • 4.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 4.2. North America Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.2.1. Corticosteroids
    • 4.2.2. Antibiotics
    • 4.2.3. Bronchodilators
    • 4.2.4. Diuretics
    • 4.2.5. Vasodilators
    • 4.2.6. Others
  • 4.3. North America Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 4.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 4.3.2. Pneumonia-induced Lung Injury
    • 4.3.3. Sepsis-induced Lung Injury
    • 4.3.4. Trauma-related Lung Injury
    • 4.3.5. Others
  • 4.4. North America Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.4.1. Intravenous
    • 4.4.2. Oral
    • 4.4.3. Inhalation
  • 4.5. North America Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.5.1. Hospital Pharmacies
    • 4.5.2. Retail Pharmacies
    • 4.5.3. Online Pharmacies
  • 4.6. North America Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.6.1. U.S. Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 4.6.2. U.S. Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 4.6.3. U.S. Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 4.6.4. U.S. Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 4.6.5. U.S. Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 4.6.6. Canada Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 4.6.7. Canada Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 4.6.8. Canada Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 4.6.9. Canada Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 4.6.10. Canada Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 4.7. BPS Analysis/Market Attractiveness Analysis

5. Europe Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 5.1. Europe Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Pharmacological Therapy
    • 5.1.2. Oxygen Therapy
    • 5.1.3. Mechanical Ventilation
    • 5.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 5.2. Europe Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.2.1. Corticosteroids
    • 5.2.2. Antibiotics
    • 5.2.3. Bronchodilators
    • 5.2.4. Diuretics
    • 5.2.5. Vasodilators
    • 5.2.6. Others
  • 5.3. Europe Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 5.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 5.3.2. Pneumonia-induced Lung Injury
    • 5.3.3. Sepsis-induced Lung Injury
    • 5.3.4. Trauma-related Lung Injury
    • 5.3.5. Others
  • 5.4. Europe Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.4.1. Intravenous
    • 5.4.2. Oral
    • 5.4.3. Inhalation
  • 5.5. Europe Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Europe Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.6.1. Germany Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.2. Germany Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.3. Germany Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.4. Germany Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.5. Germany Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.6. Italy Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.7. Italy Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.8. Italy Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.9. Italy Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.10. Italy Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.11. France Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.12. France Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.13. France Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.14. France Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.15. France Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.16. U.K. Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.17. U.K. Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.18. U.K. Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.19. U.K. Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.20. U.K. Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.21. Spain Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.22. Spain Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.23. Spain Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.24. Spain Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.25. Spain Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.26. Russia Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.27. Russia Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.28. Russia Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.29. Russia Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.30. Russia Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.31. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 5.6.32. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 5.6.33. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 5.6.34. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 5.6.35. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 5.7. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Pharmacological Therapy
    • 6.1.2. Oxygen Therapy
    • 6.1.3. Mechanical Ventilation
    • 6.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 6.2. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.2.1. Corticosteroids
    • 6.2.2. Antibiotics
    • 6.2.3. Bronchodilators
    • 6.2.4. Diuretics
    • 6.2.5. Vasodilators
    • 6.2.6. Others
  • 6.3. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 6.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 6.3.2. Pneumonia-induced Lung Injury
    • 6.3.3. Sepsis-induced Lung Injury
    • 6.3.4. Trauma-related Lung Injury
    • 6.3.5. Others
  • 6.4. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.4.1. Intravenous
    • 6.4.2. Oral
    • 6.4.3. Inhalation
  • 6.5. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.6.1. China Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.2. China Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.3. China Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.4. China Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.5. China Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.6. Japan Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.7. Japan Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.8. Japan Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.9. Japan Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.10. Japan Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.11. South Korea Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.12. South Korea Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.13. South Korea Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.14. South Korea Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.15. South Korea Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.16. India Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.17. India Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.18. India Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.19. India Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.20. India Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.21. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.22. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.23. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.24. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.25. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.26. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 6.6.27. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 6.6.28. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 6.6.29. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 6.6.30. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 6.7. BPS Analysis/Market Attractiveness Analysis

7. Latin America Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 7.1. Latin America Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Pharmacological Therapy
    • 7.1.2. Oxygen Therapy
    • 7.1.3. Mechanical Ventilation
    • 7.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 7.2. Latin America Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.2.1. Corticosteroids
    • 7.2.2. Antibiotics
    • 7.2.3. Bronchodilators
    • 7.2.4. Diuretics
    • 7.2.5. Vasodilators
    • 7.2.6. Others
  • 7.3. Latin America Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 7.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 7.3.2. Pneumonia-induced Lung Injury
    • 7.3.3. Sepsis-induced Lung Injury
    • 7.3.4. Trauma-related Lung Injury
    • 7.3.5. Others
  • 7.4. Latin America Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.4.1. Intravenous
    • 7.4.2. Oral
    • 7.4.3. Inhalation
  • 7.5. Latin America Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Latin America Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.6.1. Brazil Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.2. Brazil Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.3. Brazil Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 7.6.4. Brazil Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 7.6.5. Brazil Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.6. Mexico Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.7. Mexico Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.8. Mexico Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 7.6.9. Mexico Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 7.6.10. Mexico Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.11. Argentina Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.12. Argentina Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.13. Argentina Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 7.6.14. Argentina Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 7.6.15. Argentina Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.16. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 7.6.17. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 7.6.18. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 7.6.19. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 7.6.20. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 7.7. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Acute Lung Injury Treatment Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Pharmacological Therapy
    • 8.1.2. Oxygen Therapy
    • 8.1.3. Mechanical Ventilation
    • 8.1.4. Extracorporeal Membrane Oxygenation (ECMO)
  • 8.2. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.2.1. Corticosteroids
    • 8.2.2. Antibiotics
    • 8.2.3. Bronchodilators
    • 8.2.4. Diuretics
    • 8.2.5. Vasodilators
    • 8.2.6. Others
  • 8.3. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
    • 8.3.1. Acute Respiratory Distress Syndrome (ARDS)
    • 8.3.2. Pneumonia-induced Lung Injury
    • 8.3.3. Sepsis-induced Lung Injury
    • 8.3.4. Trauma-related Lung Injury
    • 8.3.5. Others
  • 8.4. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.4.1. Intravenous
    • 8.4.2. Oral
    • 8.4.3. Inhalation
  • 8.5. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.6.1. GCC Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.2. GCC Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.3. GCC Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.4. GCC Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.5. GCC Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.6. South Africa Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.7. South Africa Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.8. South Africa Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.9. South Africa Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.10. South Africa Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.11. Egypt Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.12. Egypt Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.13. Egypt Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.14. Egypt Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.15. Egypt Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.16. Nigeria Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.17. Nigeria Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.18. Nigeria Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.19. Nigeria Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.20. Nigeria Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.21. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
    • 8.6.22. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
    • 8.6.23. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
    • 8.6.24. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
    • 8.6.25. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
  • 8.7. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. GlaxoSmithKline plc
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Bayer AG
    • 9.4.3. Pfizer Inc.
    • 9.4.4. Teva Pharmaceutical Industries Ltd.
    • 9.4.5. Eli Lilly and Company
    • 9.4.6. Octapharma AG
    • 9.4.7. Ono Pharmaceutical Co., Ltd.
    • 9.4.8. Asklepion Pharmaceuticals, LLC
    • 9.4.9. Edesa Biotech
    • 9.4.10. Direct Biologics
    • 9.4.11. Windtree Therapeutics, Inc.
    • 9.4.12. Apeiron Biologics AG
    • 9.4.13. ReAlta Life Sciences, Inc.
    • 9.4.14. Stemedica Cell Technologies, Inc.
    • 9.4.15. Histocell

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations